Aldeyra Therapeutics has been granted a patent for formulations of methotrexate for ocular administration, specifically for treating conditions like proliferative vitreoretinopathy and intraocular inflammation. The composition includes methotrexate, sucrose, and a phosphate buffer for intravitreal administration. GlobalData’s report on Aldeyra Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Aldeyra Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Aldeyra Therapeutics's grant share as of May 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
Intravitreal methotrexate composition for treating eye diseases
A recently granted patent (Publication Number: US12005061B2) discloses a composition suitable for intravitreal administration for the treatment of intraocular lymphoma. The composition includes methotrexate at a concentration ranging from about 7 mg/mL to about 9 mg/mL, sucrose at a concentration of about 7% w/v to about 12% w/v, and a phosphate buffer. The administration volume of the composition can vary between about 40 µL to about 60 µL, with specific concentrations and pH levels outlined in the claims.
Furthermore, the patent details a method for treating primary vitreoretinal lymphoma (PVRL) using the disclosed composition. The treatment regimen involves administering the composition intravitreally to the subject in need, with specific concentrations of methotrexate, sucrose, and buffer, along with defined administration volumes and pH levels. The method includes various phases such as induction, consolidation, and maintenance, with specific frequencies of administration outlined for each phase. The patent also covers variations in treatment frequency, osmolarity, and volume of composition administered, providing a comprehensive guide for healthcare professionals treating PVRL using this innovative method.
To know more about GlobalData’s detailed insights on Aldeyra Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
